GenSight Biologics is a Gold sponsor of the 2021 ISGEDR Meeting (International Society for Genetic Eye Diseases & Retinoblastoma). Senior management will attend and be present as well as oral presentations on LUMEVOQ® and GS030 will be featured at the 2021 ISGEDR meeting in Lausanne (Switzerland) in September 2-4, 2021.
“The Phase III REFLECT Trial: Efficacy and Safety of Bilateral Gene Therapy for Leber Hereditary Optic Neuropathy (LHON)” will be presented by Bart Leroy, MD, Ghent University Hospital, Belgium (Investigator in the REFLECT trial).
- Oral Presentation
- Session 1 – Ophthalmic Genetics 3: Treatment of Inherited Retinal Disorders
- Abstract Number: OcGen31
- Thursday, September 2, 2021, 12:12 – 12:22 pm CEST
“Optogenetics: The Generic Future?” will be presented by José-Alain Sahel, MD, University of Pittsburgh School of Medicine, United States (Co-founder of GenSight Biologics).
- Oral Presentation
- Session 2 – Symposium: Gene Therapy (Nuclear Genes)
- Abstract Number: OcGenInvited5
- Thursday, September 2, 2021, 2:30 – 2:40 pm CEST
“New Insights into Leber Hereditary Optic Neuropathy” will be presented by Patrick Yu-Wai-Man, MD, University of Cambridge, United Kingdom (Investigator in the RESCUE, REVERSE and REFLECT trials).
- Oral Presentation
- Session 6 – Symposium: Mitochondrial Genetics & Optic Neuropathies
- Abstract Number: OcGenInvited10
- Saturday, September 4, 2021, 2:20 – 2:35 pm CEST
“Gene Therapy for Leber Hereditary Optic Neuropathy” will be presented by Catherine Vignal, MD, Fondation Rothschild Hospital, Paris, France (Investigator in the RESCUE, REVERSE and REFLECT trials).
- Oral Presentation
- Session 6 – Symposium: Mitochondrial Genetics & Optic Neuropathies
- Abstract Number: OcGenInvited11
- Saturday, September 4, 2021, 2:35 – 2:50 pm CEST